Barclays PLC Capricor Therapeutics, Inc. Transaction History
Barclays PLC
- $377 Billion
- Q3 2024
A detailed history of Barclays PLC transactions in Capricor Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 36,296 shares of CAPR stock, worth $671,113. This represents 0.0% of its overall portfolio holdings.
Number of Shares
36,296
Previous 36,296
-0.0%
Holding current value
$671,113
Previous $552,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding CAPR
# of Institutions
92Shares Held
8.13MCall Options Held
1.78MPut Options Held
1.4M-
Black Rock Inc. New York, NY1.63MShares$30.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.58MShares$29.2 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA638KShares$11.8 Million0.0% of portfolio
-
State Street Corp Boston, MA512KShares$9.47 Million0.0% of portfolio
-
Superstring Capital Management LP New York, NY337KShares$6.24 Million4.49% of portfolio
About CAPRICOR THERAPEUTICS, INC.
- Ticker CAPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,346,200
- Market Cap $450M
- Description
- Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for th...